← Back to Search

Unknown

[¹⁴C]-LY3537982 (Part 1) for Healthy Subjects

Phase 1

Waitlist Available

Research Sponsored by Eli Lilly and Company

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up predose on day 1 up to postdose on day 21 (part 1)

Awards & highlights

Study Summary

This trial will measure how a drug, LY3537982, is absorbed and broken down in the body of healthy participants, and check its safety and tolerability. A radioactive tracer will be used to track how much of the drug is absorbed and expelled. The trial will last up to 71 days.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ predose on day 1 up to postdose on day 21 (part 1)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~predose on day 1 up to postdose on day 21 (part 1)

This trial's timeline: 3 weeks for screening, Varies for treatment, and predose on day 1 up to postdose on day 21 (part 1) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

PK: Absolute Bioavailability (F) of LY3537982

PK: Cumulative Fefeces

PK: Cumulative Feur

+3 more

Trial Design

2Treatment groups

Experimental Treatment

Group I: [¹⁴C]-LY3537982 + LY3537982 (Part 2)Experimental Treatment2 Interventions

Single dose of LY3537982 administered orally followed by [¹⁴C]-LY3537982 administered intravenously (IV).

Group II: [¹⁴C]-LY3537982 (Part 1)Experimental Treatment1 Intervention

Single dose of [¹⁴C]-LY3537982 administered orally.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

LY3537982

2023

Completed Phase 1

~100

[¹⁴C]-LY3537982

2023

Completed Phase 1

~20

Do I qualify?Apply below to find out

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor

2,617 Previous Clinical Trials

3,201,184 Total Patients Enrolled

Loxo Oncology, Inc.Industry Sponsor

66 Previous Clinical Trials

9,853 Total Patients Enrolled

Yingying Guo-Avrutin, MD, PhDStudy DirectorLoxo Oncology, Inc.

3 Previous Clinical Trials

120 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is [¹⁴C]-LY3537982 (Part 1) generally harmless to humans?

"Due to the lack of evidence for safety and efficacy, [¹⁴C]-LY3537982 (Part 1) has been given a score of 1 on our team's risk assessment scale."

Answered by AI

Who does this trial specifically target as ideal participants?

"To qualify for consideration in this trial, prospective participants must be within the ages of 18 and 55, have no major health issues, and should note that 16 total people are being recruited."

Answered by AI

Does this trial only accept individuals of a specific age bracket?

"This clinical trial is available to adults between the ages of 18 and 55. For those under 18 years old, there are currently 55 trials registered; for patients over 65, 376 studies have been posted."

Answered by AI

Are there any open enrollment opportunities for this clinical trial?

"The most recent edit to the clinicaltrials.gov page for this trial was on June 4th, 2023; evidently, recruitment is now closed. Although hopeful participants are no longer being sought out, 810 other medical experiments are actively seeking enrolment at present."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Study of [14C]-LY3537982 in Healthy Participants

2023. "A Study of [14C]-LY3537982 in Healthy Participants". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05901311.